Abstract: A point-of-care test (POCT) for Chlamydia trachomatis detection is an urgent public health need. Technological advances in diagnostics have made solutions possible. Yet no reliable POCT exists. Our goal was to address the gap between Chlamydia POCT needs and successful POCT development by determining which characteristics of POCTs are most critical and if any flexibility in the attributes assigned those characteristics exists between technology developer and end user.
D espite many years of effort and many valid attempts to develop point-of-care tests (POCTs), there are very few marketed POCTs for sexually transmitted infections (STIs) available today. 1, 2 This begs the question why there is still no POCT available for many of our common STIs especially when there are such technological advances in other fields of medicine? Why do tests developed for bacterial infections such as streptococcal pharyngitis and viruses such as human immunodeficiency virus fail to translate to other STIs? What prevents these rapid tests performed in the clinical laboratory from moving to the personal test market, that is, patients waiting at clinics or home testing? Identifying the key gaps in technology, which are preventing the acceptance or development of tests for the personal POCT market for STIs, was the focus of our investigations. In particular, we wanted to address the apparent gap between the tests being developed by industry and the user's expectations of a valid POCT for STIs. 3 Our decision to focus on POCT needs for chlamydia diagnostics was based on the input from our large-scale focus group study and large survey of experts in POCT. 4, 5 Physicians and clinical staff from public and private clinical sites ranked ''onsite/within-visit'' chlamydia testing as the most pressing need for current clinical diagnostic POCT. Although the current nucleic acid amplification tests (NAATs) meet the requirements for sensitivity and specificity for chlamydia diagnostic assays, current NAATs, which are the clinically accepted assays for chlamydia diagnosis, they are too complicated, too-labor intensive, or not appropriately time sensitive to meet the needs for an in-clinic POCT. 5 In our online survey, which invited STI experts and clinicians to ''build their own test,'' the characteristics selected were high sensitivity and low cost; however, within a fairly narrow range of time (5Y25 minutes), there was no clear preference, suggesting that time was a factor that could be granted some leeway to develop assays to meet the clinical need. 5 To investigate this aspect further, we used a tool originally developed to bring together experts with a variety of viewpoints to address a common problem known as a warfare analysis laboratory exercise (WALEX). 6 As part of the WALEX, anonymous on-site surveys using discrete choice experiments (DCEs) were used. 7, 8 The goal of these combined processes, WALEX combined with DCE, was to identify the ranges of attributes, which would promote test acceptance and identify the interdependency between them rather than present desirable attributes as discrete independent single values, which developers need to design with rigid adherence. We wished to define the path to the best achievable design today rather than the best theoretical design for the perfect test.
METHODS

WALEX Description
The WALEX process involves facility design, analytical planning, and software to enhance group interaction. As shown in Figure 1 , infrastructure, hardware, software, and people are part of the design. The challenge of this process is to capture all of the diverse viewpoints and assemble them into supporting documentation. The electronic seminar support system is a suite of software tools that supports collaboration by networking participants through laptop computers. The physical configuration of warfare analysis laboratory (WAL) includes the main seminar area, electronic support of collaborative discussions, easy availability of technical and analytic data, integrated audio and visual infrastructure, and advanced modeling and simulation capabilities. During briefings and moderated discussions, participants can enter comments that can be viewed by all other participants using computer groupware. If necessary, they can enter their comments anonymously. With a large group of participants in this type of setting, the oral debate can range across issues unevenly, leaving some incompletely examined. Some participants dominate discussions by virtue of their authority or personality. Often, sidebar conversations take place between certain participants, distracting from the main issue. The electronic seminar support can overcome these weaknesses of a large group discussion by promoting the exchange of opinions and assessments, with a candor uninfluenced by rank or organizational hierarchy through anonymous comments. The electronic discussion (e-discussion) promotes candid audience input regardless of the participant's position, personality, or verbal communication skills. It also permits electronic surveying and voting of the audience and provides sophisticated decision analysis tools designed to quantify subjective assessments from the participants.
The WALEX process addressing Chlamydia POCT development was initiated by establishing the parameters of the problem to be addressed related to POCT for STIs. The experts from the Center for POCT STI were interviewed by the WALEX team members with regard to the current standards of STI POCT development. Current standards were discussed, and specific gaps were identified in the design or in the attributes of specific tests. In addition, information from focus groups organized by the center was used to identify areas in which there are perceived gaps in the current need. 4 These issues were used to design the overall problem by asking participants to identify the most critical characteristics in each of the areas for a successful STI POCT. On the basis of the needs assessments, from the focus groups, chlamydia had been selected as the most important STI to target for development of an STI POCT and was used as the subject of the WALEX.
Participants and Instructions
Participant recruitment for the WALEX was by-invitation only, and names of 30 participants were recommended by members of the Center for POCT STD, including clinicians, laboratory professionals, and regulatory officials, who had sufficient expertise in STIs; and experts in engineering sensor designs, or personnel, who interacted with the US Food and Drug Administration (FDA). One company currently developing POCT for chlamydia was also invited to the WALEX to provide an additional perspective from a commercial developer's viewpoint. Before the WALEX, all participants were sent a reading list with publications grouped into 4 subject areas: the WALEX process, STI characteristics and needs assessments, POCT design needs, and POCT diagnostic technology.
The WALEX was initiated with a short instructional briefing and overview of the issues and problems, which needed to be addressed during the 4-hour session. A moderator presented the following primary topic areas: Characteristics of POCT/technical design, Manufacturing transition, Risk, and Market acceptance. Each area was supported by a list of questions for group discussion. All discussions and e-discussions were recorded for review and subsequent summation.
WALEX Survey Design and Analysis
Before the WALEX, the survey questions were prepared based on interviews with the center staff and results of the focus group discussions. These inputs were used to design a parameter list and the ranges at which a POCT should operate. Regulatory guidelines for test approval were reviewed and used to determine which parameters were not optional and had minimal federal standards for test approval. This information was used to design a scenario for the choice experiments. Because federal regulations require that the specificity and sensitivity of a new test for STD are not defined by end users or developers, these 2 parameters were fixed in the scenario and not open to choice by the participants as they would be in actual practice. The assumption was that any test FDA cleared and marketed would have to meet these minimal standards and, therefore, was not a matter of choice for this WALEX.
Design of Experiments and DCEs
The design of experiment (DOE) method was used to develop the extremes of each node (parameter) to be used in the force choice questions. 9 Discrete choice experiment is a subset of DOEs originally used to develop market surveys. Using 2 Â 2 matrix factorial design for all the attribute levels listed in Table 1 10 Key characteristics important for a POCT for chlamydia were sample type, assay time, sampling capacity, and assay cost (Table 1) . Assay time and cost were subdivided. Assay time divisions reflected the difference between manual sample manipulation time (hands-on time), sometimes referred to as processing time, and time-to-assay result (instrument time). Cost was subdivided into the following: (1) disposable assay costs, which are continuous costs; and (2) instrument costs, which are frequently onetime costs. A range for each characteristic was developed (Table 1) based on the input from clinical experts from the center interviewed before the WALEX. The final choice survey was designed using DCE to derive 16 pairs of forced choice questions (Table 2) . Discrete choice experimental methodology has been described as a means to evaluate compromise. 11 Most of the choice pairs contained 2 least ideal combinations, and survey participants were forced to select the better of the 2 less desirable choices.
Data Analysis
Data were collected electronically and analyzed using JMP version 8 (SAS Institute, Inc, Cary, NC) with application of Firth's unbiased estimator. The analysis was conducted by applying Firth's unbiased estimator available in JMP software, and the results are shown in Figure 2 .
12 Choice modeling, a form of conditional logistic regression, is a method to use a linear model to model choices based on response attributes and not solely on subject characteristics. 13 The effect of likelihood is a graphical tool for ranking causes from most significant (low probability relative to W 2 value) to least significant (high probability relative to W 2 ). The effect likelihood ratio test, similar to a Pareto chart, addresses the factors that have the greatest impact on outcome. In this test, however, the null hypothesis states that the attribute or variable has no effect on the probability of success of a POCT.
Prediction Profiler is a JMP graphical representation of utility and allows one to look for variation in each attribute as an independent and interdependent variable. 12 To address the interdependence of each attribute and the effect of compromise, analysis of survey data was evaluated based on its desirability as independent and dependent conditions. Desirability as defined by JMP software is a technique by which multiple attributes can be optimized to obtain the best characteristics for as many attributes simultaneously. As independent variables, desirability for each individual attribute was determined at maximum desirability (1.0). For interdependent variables, desirability is allowed to vary to the optimal level for all factors even if desirability for a single factor is less than its optimal independent value.
RESULTS
Summary of WALEX Discussion Points
Characteristics and associated attributes for use in the choice surveys were selected from inputs obtained from focus groups conducted among health professionals. 4 The focus of the WALEX and forced choice surveys was POCT for chlamydia. In prior work, physicians from public and private sector laboratories selected the need for rapid tests for this organism as the top need. 5 Under each set of choice questions, Table 1 summarizes the feedback that we received from choices made by health professionals, clinical laboratorians, and companies regarding acceptable features of POCT. In each case, we included the percent of choices from all participants. An example of this is reflected in the choices for instrument assay time or the time from sample to result. One participant stated that ''most focus groups say, yeah, they'd like to have five minutes [for a POCT but], 20 minutes is acceptable. But we all know that people sit in emergency Owing to conflict of interest restrictions, 5 of the government sponsors were not permitted to provide responses to the survey questions. Therefore, there is a slight difference in the makeup of the groups who participated in the WALEX and those who responded to the survey questions (33% vs 18%). The other 3 groups composed of researchers, physicians, and other participants averaged 6 participant per group T1; thus, their contributions to the survey provided nearly equivalent inputs of 31%, 23%, and 27%, respectively. Finally, we evaluated the familiarity of the survey participants (n = 22) with the issues associated with chlamydia diagnostics, point-of-care diagnostics, and diagnostic testing. For the most part, the participants stated they were familiar with the use of or the design of point-of-care tests (52%). However, a much smaller percentage of participants were familiar with Chlamydia; 22% of the survey participants were specifically familiar with Chlamydia as represented by those clinicians (9%) and researchers (13%) with expertise in the treatment or study of this organism. The remaining survey participants (26%) were familiar with requirements for acceptance of diagnostics assays in clinical settings. Before administration of the survey questions shown in Table 2 , the WALEX was conducted to address specific topics associated with the development and transition of successful assays to the clinical market. Shown below are the results from the 4 topic areas discussed in detail: technical design of POCT, transition from research and development to testing and manufacturing, risk assessment, and market acceptance.
Technical Design of POCT
Key factors discussed included patient acceptance of sampling location and patient willingness to self-sample, sensitivity of sample types based on organism load associated with sampling location, differences in processing requirements based on site, sensitivity versus specificity, and time to result ( Table 3 ). The interdependency of these factors in the design of an appropriate test was evident from the ensuing discussion. Sampling location (vaginal, cervical, penile, urine) and type (swab vs liquid) were affected by inferred sensitivity owing to organism load and dilution factor. Urine, although preferred by the patient community and for the home POCT, was not ideal for chlamydia testing as stated by clinical professionals. To obtain the necessary sensitivity, the urine concentration or the fractionated sample collection (mid stream, first burst, or total) is needed, which adds to the complexity, equipment, and training needed to administer the POCT. Sensitivity and time to result are also affected by administration of Chlamydia POCT as a screen or for confirmation of a diagnosis as acknowledged by participants. A 2-tier test composed of a rapid but less sensitive POCT followed by a slower but more sensitive confirmatory test for all first-tiernegative samples to be modeled after the methodology used for ''streptococcal'' testing was suggested. An assumption of this model was that higher false-positive rates would be tolerated; this assumption was rejected by some participants because of variations in geographic prevalence rates and because of higher costs. One participant stated ''using a specificity under 96% and a prevalence of 1%'' resulted ''in an estimated PPV of 26%,'' making ''the value of such a test nearly irrelevant.'' A final viewpoint expressed was that a ''one-size-fits-all'' Chlamydia POCT may not be the correct solution.
Transition From Research and Development to Testing and Manufacturing
In the next part of the WALEX, the regulatory requirement and preferences regarding the format in which tests are packaged was the focus (Table 3 ). The most important detail regarding the approval and clearance of the test by FDA is the newest requirements for medical devices inclusive of Clinical Laboratory Improvement Amendments (CLIA)Ywaived test to exhibit a performance of at least 95% of a currently accepted reference test. 14 The ability of immunoassays to meet the 95% agreement with clinically accepted reference tests was considered to be challenging when the reference test is NAAT noted to be the current clinical standard for chlamydia diagnostics by several participants. Even CLIA-waived POCTs must be compared against performance conducted by a trained professional. Participants made the point that faster POCT with lower sensitivity may have a bigger public health impact for chlamydia than a perfect test that is not POCT. Two other issues relating to manufacturing of the final POCT designVthe number of tests that could be run simultaneously and the frequency of quality controlVwere discussed in detail. Although developers intended to package POCT as 1 test per patient, clinicians noted that parallel (multisample) processing would be needed for POCT to be used in the clinic. Flexibility to meet uneven flow of patients through a clinic was noted as a negative impact in batch processing for POCT. Participants stated that this would defeat the advantage of rapidity in POCT. Clinical laboratorians in the group noted with some irritation the problems encountered in the packaging guidance for quality controls noting that manufacturers need to put more thought in addressing this. For some rapid test for other STIs, controls need to be run so frequently that significant amounts of time and labor are devoted to quality control rather than sample testing.
Risk Assessment and Cost
Risk in the development and marketing of POCT for Chlamydia was not seen as an issue, although cost per test was 
Market Acceptance
When queried, the WALEX group, defined as the end user of POCT as clinicians, clinical laboratories, and patients indicating that the design of POCT for Chlamydia, has many potential targets (Table 1) . One research stated that adolescent focus groups indicated that they would accept POCT for Chlamydia even if they had higher false-positive rates. Patient privacy issues were noted to be a key driver for POCT acceptance and home testing. Participants described the potential complications of patient-based home testing as a concern when patients self-medicated based on the outcome of home tests. The potential for misinterpretation and the operator errors were seen as negative influences on home testing for Chlamydia. Notably, home sampling with mail in-testing at established centers was viewed as a favorable solution.
Forced Choice Survey Results
The frequency of each forced choice within the pair is shown in the second column and reflects the selection by all WALEX survey participants ( Table 2 ). The survey data were modeled using Firth's unbiased estimator (JMP version 8.0; SAS, Inc) (Fig. 2) . By posing a set of choices, which carefully balances the choices in a balanced designed matrix of questions, a quantitative statistical evaluation of the respondents' true desires is estimated using the bias-corrected maximum likelihood estimator. 16 The parameter estimate indicating the coefficients on a linear regression and the W 2 probability are shown in the lower table. As can be seen in the effect likelihood ratio tests, the smallest W 2 9 probability is assigned to the cost per assay, followed by instrument processing time, number of samples per batch (also defined in WALEX as run), and instrument setup cost, and sample type hands-on time just barely made the cutoff for significance (G0.05), although sample type was not determined to be a significant factor based on its attribute choices of 5 or 10 minutes.
The largest negative coefficient in the parameter estimates table is shown for urine as a sample type. This negative bias may be reflective of the WALEX discussion in which the value of urine samples may be compromised by the absence of clinical data indicative of sufficient organism load and absence of appropriate sampling preparation methods for current POCT.
As shown in Figure 2 , statistically significant characteristics (G0.05), based on failure of the null hypothesis for each encompass choice variation, according the attributes listed in Table 1 , are likely candidates to affect the success of a POCT. The independent effect for the choices of each variable are often called marginals. The sum of the marginals in a particular combination of variables chosen is called the utility of that choice. A graphical representation of this utility function is called the prediction profiler, shown in Figure 3 . 12 The prediction profile calculates the utility of a choice set by being able to interactively change the test variables or factors independently from each other in JMP 8. Thus, for this analysis, the following 6 characteristics were the most desirable independent attribute levels ( Fig. 3A) : vaginal swab, a 5-minute hands-on time, a 5-minute instrument process time, 4 samples per batch, a $5000 instrument setup cost, and a $10 cost per assay, the utility (also called response), were calculated as: In contrast, when choices were forced to select the best combination of attributes, survey participants made their selections based on compromise. Less important ideal attributes were sacrificed to preserve key characteristics. This compromise is represented by the prediction profiler graph shown in Figure 3B . In this case, the maximum utility for the attributes of vaginal swab, a 10-minute hands-on time, a 240-minute instrument process time, 4 samples per batch, a $10,000 instrument setup cost, and a $10 cost per assay were selected. When desirability was maximized, there is no compromise for the desired attributes of higher (Fig. 4) . The areas within the boundaries define the ranges of attributes or trade space for assay development. Notably, the configuration and area bounded in the spider chart varied by expertise, supporting the WALEX quote that a ''one-size-fits-all'' Chlamydia POCT may not be the correct solution.
DISCUSSION
Our studies demonstrate 1 approach that can be used to (1) address the causes for the gap between technology solutions and needs and (2) find practical and acceptable solutions by partnering industry, regulatory, and health professionals as unified stakeholders in identifying the most practical path forward. On the basis of our research focus, we used the process of WALEX in combination with DCE to address the needs for better Chlamydia tests. The need for improved methods for detection of chlamydial infections has been well established by our center and a number of other groups for the last decade.
1Y5 The recommendation for POCT has been described, and the implementation of more robust screening has been addressed as a national priority. 17 A key advantage of the WALEX is the opportunity provided to the participants to educate and inform each other from different expert viewpoints. For the WALEX to be successful, the right number and mix of people is critical to a successful outcome. This tool can provide participants with a better understanding of the issues or restrictions faced by developers (industry) and end users (clinicians), while giving sponsors (funding agencies, payers) a voice in the development of a solution. Rigid adherence to narrow performance characteristics by the user community is likely off-putting to commercial developers and may well be a significant cause for the gap between the need for and the development of POCTs. The addition of DCE to the WALEX assisted us in capturing the process of consensus and in validating key parameters in potential technical solutions. In this way, the WALEX process combined with DCE developers may view the challenge of POCT development for targets like chlamydia more favorably, thus attracting more developers and promoting greater success.
Unlike focus groups, the WALEX intentionally mixes experts with differing and sometimes opposing views not for the purpose of ''group thinking'' but for the purpose of achieving consensus on the best solution or path forward. As a result, the solutions achieved in the WALEX may be different from those of a focus group as demonstrated by our WALEX and DCE methods. As described in our study, acceptable test characteristics could support testing times of up to 4 hours if the cost of the test could be kept to less than US $10. In contrast, our center has conducted studies among focus groups and used surveys conducted among clinicians involved in STI testing who indicated a time window of only 20 minutes. 5 This difference may be attributed to the interaction among WALEX members to compromise on the best practical solution rather than the ideal solution. This trade-off provides developers flexibility during the development process to select the most cost-effective technology options and guidance with regard to technical decisions not only in making a test but also in market acceptance in an appropriate target population.
In summary, we have described a new methodology for developing compromise concessions to a problem using inputs from diverse viewpoints in the affected community. To use this tool effectively, it is important to do adequate preparation before the actual WALEX and include all who may be stakeholders in the outcome. All survey participants had the basis for an in-depth understanding of the characteristics of diagnostic tests, and 74% of the participants were specifically familiar with the needs for POCT or POCT for Chlamydia.
Our study has limitations. One caveat to our studies is that payers (ie, health maintenance organizations, federal medical insurance programs, and insurers) who are stakeholders in this process were not included in our WALEX. We recognize their absence as a source of potential bias in the outcome and are attempting to include them in future WALEX.
We conclude that the WALEX process combined with forced choice surveys (1) is an effective means to rapidly evaluate technological gaps, (2) provides an opportunity for crossfertilization and better understanding of technology needs from multiple viewpoints, and (3) helps focus a multidisciplinary team on providing practice solutions to technology challenges. Although this WALEX focused participants on the needs of 1 particular POC technology under development, we will investigate the appropriateness of this tool in providing broader industry guidance and education on critical test attributes by including multiple developers in future WALEX meetings with the possibility that the best solutions may lie in the innovation among multiple technologies. It is hoped that this tool will prove to be accurate and useful in bridging the technology gaps that are inhibiting adoption of successful POCT for targets important to public health such as chlamydia.
